WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 10, Issue 13, 1091-1112. Review Article ISSN 2277–7105

A REVIEW ON MUCORMYCOSIS

Dhruvi Kasvala*, Priyanshi Monpara, Prof. Pooja Patel and Dr. Umesh Upadhyay

Sigma Institute of Pharmacy(261), Ajwanimetaroad, Bakrol, Vadodara, Gujarat-390019.

Article Received on
09 Sept. 2021,

Revised on 30 Sept. 2021,
Accepted on 21 Oct. 2021

DOI: 10.20959/wjpr202113-22179

***Corresponding Author**
Dhruvi Kasvala
Sigma Institute of Pharmacy(261), Ajwanimetaroad, Bakrol, Vadodara, Gujarat-390019.

ABSTRACT

The Zygomycetes class is divided into two orders: Mucorales and Entomophthorales. These two orders create infections that are significantly different. Mucormycosis is an angioinvasive infection caused by Mucorales genera (Rhizopus, Mucor, Rhizomucor, Absidia, Apophysomyces, Cunninghamella, and Saksenaea). Mucormycosis can affect the rhino-orbito-cerebral region, the lungs, the skin, or the gastrointestinal tract. Immune-compromising disorders include haematological malignancies, bone marrow or peripheral blood stem cell transplantation, neutropenia, solid organ transplantation, diabetes mellitus with or without ketoacidosis, corticosteroids, and deferoxamine therapy for iron overload.A satisfactory outcome requires early identification, treatment of the underlying medical issue, surgery, and the use of an amphotericin B product. The order's genera In immunocompetent people, the entomophthorales cause entomophthoramycosis, a chronic subcutaneous infection. Tropical and subtropical regions are conducive to the spread of this virus. Basidiobolus is a genus of bacteria that causes a chronic subcutaneous infection of the thigh, buttock, and/or trunk. It has been observed that it occasionally affects the gastrointestinal tract. A persistent infection of the nasal submucosa and subcutaneous tissue of the nose and face is caused by the genus Conidiobolus. The clinical manifestations will be discussed in this study.

KEYWORDS: Mucormycosis, entomophthoramycosis, zygomycetes, Mucorales, Entomophthorales, Mucor, Rhizopus, Apophysomyces, Conidiobolus, Basidiobstud.

INTRODUCTION

Baker coined the phrase "mucormycosis.".[1] It refers to a variety of diseases caused by fungi belonging to the order Mucorales. Mucormycosis is a deadly fungal infection that affects immunocompromised people. These infections are becoming more common, and they're

linked to low survival rates.

Mucorales disease refers to a group of diseases caused by fungi in the order Mucorales. Mucormycosis is a deadly fungal infection that affects immunocompromised people. These infections are becoming more widespread, and they are linked to extremely low survival rates.[2] Mucormycosis is a granulomatous, acutely infective, and opportunistic infection caused by fungi belonging to the Photometers class, which is part of the Mucoromycotina subphylum. Mucormycosis is a granulomatous, acutely infective, and opportunistic infection caused by fungi belonging to the Phycomycetes class, which is part of the Mucoromycotina subphylum. Hibbett et al. also reported a higher-level phylogenetic categorization of these fungi.[3] Phycomycetes are divided into various genera, but Rhizopus, Mucor, and Absidia are the most typically implicated inmucormycosis. 70 percent of documented cases of CROM are caused by Rhizopus.

There are a variety of different fungi that can cause lesions in the eye and orbit, but the Phycomycetes are particularly interesting. These organisms can be found in a variety of places, including bread mould, dirt, manure, and rotting vegetation, and are typically airborne. Because mucormycosis is a systemic disease, it can damage the lungs, kidneys, bones, bladder, gastrointestinal tract, skin (through contaminated nonsterile adhesive tape), heart, and brain; nevertheless, CROM is the most frequent variety of mucormycosis. CROM is the most commontype of mucormycosis.[4]

Mucormycosis is a fungal infection caused by fungus in the Mucorales order.[3] Mucormycosis is caused by uncontrolled diabetes mellitus in ketoacidosis, various kinds of metabolic acidosis, corticosteroid medication, organ or bone marrow transplantation, neutropenia, trauma and burns, malignant hematologic diseases, and deferoxamine therapy in hemodialysis patients.[5,6,7] The number of people at risk for this lethal illness is significantly increasing due to the rising prevalence of diabetes mellitus, cancer, and organ transplantation in the ageing US population.[8] Invasive fungal diseases are a leading cause of morbidity and mortality in the United States. For characterising various sorts of infections and enhancing the consistency and reproducibility of studies on these infections, an uniform set of definitions is critical.

The original classifications of confirmed, probable, and possible invasive fungal illnesses have been retained in the new definitions, but the concept of 'probable' has been enlarged, and the

breadth of the 'possible' group has been lowered. The 'confirmed' invasive fungal illness category applies to all patients, regardless of whether or not they are immunocompromised, but the 'likely and possible' categories are just for immunocompromised patients.Only patients are allowed.[9] Mucormycosis is characterised by infarction and necrosis in the host tissue caused by hyphae invasion of the vasculature, which begins with a particular interaction with endothelial cells. Rhino- orbito-cerebral and pulmonary are the most common clinical manifestations. Increased incidence has been documented in multicenter and single-center investigations, owing to an increase in the at-risk population and improved diagnostic methods.[10,11]

Mucormycosis is an uncommon and dangerous clinical condition caused by a Mucorales fungus. It's a potentially fatal infection with a high morbidity and fatality rate. It's a fungal infection that takes advantage of the situation. Previous literature was the first to describe mucormycosis.[12] It's also known as zygomycosis, and it's a fungal infection that's innocuous to healthy people but deadly to immunocompromised patients.Rhizopus species are the most prevalent organisms that cause mucormycosis. Predisposing circumstances include diabetic ketoacidosis and neutropenia. This potentially fatal infection has a strong predilection for arteries. They have a proclivity for spreading into arteries and lymphatics, resulting in the production of Mucor thrombi and tissue ischemia and infarction. This fungus frequently dissects the internal elastic lamina from the medium of blood arteries, causing significant endothelial damage and thrombosis. It's also known as zygomycosis, and it's completely harmless to healthy people.[13]

The most prevalent types of mucormycosis infections in clinical practise are infections of the paranasal sinuses (39 percent), lungs (24 percent), skin (19 percent), brain (9 percent), and gastrointestinal (7 percent), with other types being exceedingly rare.[14]

Historical Review of Mucormycosis

For over a century, Phycomycetes fungi have been blamed for a variety of ailments including pernicious anaemia, cancer, and madura foot. Meyer discovered the pathogenicity of mucor germs in 181.[15]

However, it wasn't until 1876 that enough evidence was gathered to link these organisms to the human disease phycomycosis.[16] Gregory et al., published in 1943, demonstrated the propensity of phycomycotic infection in diabetic patients and described the diseases that

eventually became known as the clinical trio of diabetes mellitus, orbital cellulitis, and meningocerebritis.[17] In 1955, Harris published the first example of a patient who had survived cerebro-rhino orbitalmycosis (CROM).[18]

TYPES OF MUCORMYCOSIS

Gastrointestinal mucormycosis

Mucormycosis can affect any organ system, although the nasal sinuses, orbit, and brain (rhino- orbital-cerebral) or the lung are the most prevalent manifestations. For a long time, Gastrointestinal mucormycosis remained uncommon, especially in developed countries. However,the number of instances of stomach and Gastrointestinal mucormycosis indexed on PubMed has increased dramatically during the last two decades, notably in the last decade. A PubMed search for the title phrases "gastric" or "gastrointestinal" and "mucormycosis" or "zygomycosis" turned up 8 papers from 1959 to 1989 (31 years), 23 papers from 1990 to 1999 (10 years), and 50 papers from 2000 to 2002.[19]

The symptoms of Gastrointestinal mucormycosis vary depending on the site of infection. The most common symptoms are nonspecific abdominal pain and distention, as well as nausea and vomiting. Fever and hematochezia are also possible side effects. The patient is frequently misdiagnosed as having an intra-abdominal abscess.

A biopsy of the suspicious area during surgery or an endoscopy may be used to make the diagnosis. Due to contamination of wooden applicators used to mix medications for patients with nasogastric feeding tubes, an iatrogenic outbreak of gastric mucormycosis occurred recently.[20]

Rhinocerebral Mucormycosis

The nasal cavity, paranasal sinuses, orbital, and brain tissues are all involved in the rhinocerebral type. The rhinocerebral, rhinoorbital, and rhinomaxillaris variants of this clinical condition are further divided based on the fungus's location.[21] The sinonasal subtype is very important, because the troublesome location and difficult, late-occurring visible signs detected in late advanced clinical stages can frequently decide the fate of the patient (Table 1).[21] In the case of rhinoorbital mucormycosis, any material for microscopic examination is taken mostly from nose secretions, the nasal cavity and a biopsy of the infected tissue (Table 2).[22]

Table 1: Clinical stages of rhinocerebral mucormycosis depend on the location of the fungus.

Stage 1	Infection of the nasal cavity mucosa, sinuses, local vascular thrombosis. This leads torapid spread of disease to soft tissue(face skin, oral cavity mucosa). Infection may pass through the cartilage and bone barrier.
Stage 2	Infection of orbits and retinal vessels.
Stage 3	Intracranial invasion(through the orbital apex, cribriform plate of ethnocide bone and ethmoidal fovea).

Table 2: The possible diagnostic methods and their effectiveness.

Radiological imaging	CT, MRI	In the CT image are visible changes in the bone(sinus bone wall destruction), inverted ”halo ”mucosal thickening, swelling of soft tissue and extra ocular muscles, exophthalmia. MRI reveals early changes in the soft tissues, intracraniallesions, involvement of the cavernous sinus, early vascular invasion.
Microbiological culture	Fungus culture from biopsy	Often it gives a false negative result due to the material being damaged during the process of obtaining it. A biopsy should be obtained from the depth of infected tissues. Microbiological culture is currentlyat the level of 50-71% of efficiency and shows an upward trend.
Histopathology	Staining : H+E, Gomorigrott, PAS	Tissue necrosis, angioinvasion with obstruction and the presence of characteristic broad, non- septate hyphae with branching at right-angle
Moleculat techniques	e. g.:PCR, RFLP, DNAsequencing, PCR-product melting curve	Analysis of the pathogen’s genetic material

Pulmonary mucormycosis

PM is relatively uncommon compared with other fungal infections of the lung, knowledge of its radiologic appearance and evolution is important because of the high morbidity and mortality rates in infected patients. The imaging findings can be nonspecific, but there are some specific radiologic clues that can aid diagnosis. Because early treatment with antifungal agents improves survival, the radiologist can play a key role in treatment of the patient.[23] If feasible, attempts toreverse the underlying predisposing factors for infection should be made. Treatment may include control of blood glucose levels, treatment of metabolic acidosis, or tapering ofimmunosuppressive agents.[29]

Surgery is recommended for patients with localized disease and results in improved outcomes compared with in those treated with antifungal therapy alone.[30,31] Surgery is usually reservedfor patients with unifocal disease and can consist of wedge resection, lobectomy, or pneumonectomy (Fig 14). Surgery for bilateral disease is uncommon but has been shown to be effective for source control.[32]



A. **B.** **C.**

Figure 1: Surgical treatment of PM in a 51 year old man with renal and stem cell transplants complicated by graft versus host disease. (A). Axial CT image of the left lower lobe shows a nodule with mild surrounding ground-glass opacity.(B) Axial CT image obtained 1 month later depicts an enlarged nodule.(C) Axial CT image obtained at follow-up 5 months after surgery shows complete resolution with no recurrences.

Cutaneous mucormycosis

There are two types of Cutaneous mucormicosis: primary and secondary. The skin is infected in primary disease by direct injection, and secondary disease is spread from other places, most commonly from a rhinocerebral infection. 3 It can be classified as localised, deep, or widespread depending on the pattern of infection. A total of 176 patients were found to have skin involvement in a study of 929 cases. The majority of these cases remained confined to the skin's whole depth, with only 24% extending to bone or muscle and 20% exhibiting hematogenous spread to noncontiguous organs.[24] The arms and legs are the most affected parts of the skin. The scalp, the face, and other parts of the body can also be affected. Fig 2.[28]



Figure 2: Cutaneous lesion of Mucormycosis.



Figure 3: Ulceration with necrotic tissue in the eyelid with involvement of the eye.



Figure 4: Cutaneous lesion of Mucormycosis.

Disseminated mucormycosis

The disseminated form of zygomycetes infection, which involves two or more noncontiguous organ systems, is highly rare and usually occurs in critically immunocompromised people.[32,33] Disseminated mucormycosis has nonspecific manifestation, which causes to hamper the diagnosis.[34] In our situation, a thorough diagnosis was hampered by the disease's nonspecific appearance as well as its quick and virulent course.In patients who do not have any immunocompromising conditions, direct inoculation of mucormycosis organisms is a common method of infection.

The infection that results can spread to the cutaneous, subcutaneous, fat, muscle, and skeletal tissues. It may also spread to deep organs in rare circumstances. Extensive bed sores in the sacral area in our patient could be a major risk factor and a channel for infection development and spread. In Disseminated mucormycosis, the lung and brain are commonly affected, as they were in our case.[35]

Differentiating mucormycosis from aspergillus species is a difficult task in histological diagnosis. Zygomycetes have a distinct shape, with bigger hyphae (520 m in width) than Aspergillus species hyphae (35 m in width). The hyphae of zygomycetes exhibit little septation and branching. In contrast to most other harmful fungi, which exhibit acute angle branching, these few branches are at random angles, including straight angles and other nonacute angles. Zygomycete hyphae frequently collapse in tissue sections, giving the appearance of a twisted ribbon. Differentiation is a major difficulty in histopathological diagnosis.[36] The only hope for treatment is rapid diagnosis,correction of predisposing factors, surgical debridement of necrotic tissue and antifungal therapy.[37]

PATHOPHYSIOLOGY

New therapeutic options for invasive fungal illness have been developed as a result of a better understanding of the aetiology of mucormycosis. For example, it is now known that iron metabolism plays a key role in disease regulation, and that deferoxamine predisposes individuals to mucormycosis by delivering iron to the fungus in an inefficient manner. New therapeutic options for invasive fungal illness have been developed as a result of a better understanding of the aetiology of mucormycosis. For example, it is now well understood that iron metabolism plays a critical role in disease regulation, and that deferoxamine predisposes patients to mucormycosis infection by inappropriate.[87]

The disease-causing fungi's spongiospores are 3—6m in diameter, and asexual spore production is thought to be the origin of human infections. Mucorales are non-septate irregular hyphae with right-angled branches that can reach a length of 200 metres. Despite their ability to phagocytoze the spores, immunocompetent hosts can acquire cutaneous infections and invasive infections.[88]

Patients who are immunocompromised or who have metabolic abnormalities are prone to mucormycosis. Neutrophils play a major role in the defense of the host against mucormycosis.[89]

Due to the active ketone reductase system in the rhizopus, ketoacidosis, low oxygen tension, and hyperglycemia in diabetics provide a perfect environment for the fungus to flourish.[87] Ketoacidosis decreases thebinflammatory response of the body and delays the local aggregation of granulocytes and fibroblasts. The sera of diabetics appear to lack a dialyzable anti- fungal inhibitory factor. The spores attach to the nasal and oral mucosae upon which

massive proliferation takes place,and they geminate into hyphae. Polymorphonuclear cells are less effective at removing hyphaeunder metabolic hypoxic state as is often found in patients with mucormycosis associated with diabetes mellitus, thereby abetting establishment of the infection.Mucor is an angiotropic fungus that has a predilection for the internal elastic lamina of the blood vessels, especially the arteries, and it eventually invades the lymphatics and veins. The fungus directly involves blood vessels by inducing arteritis and thrombotic vascular occlusions, which results in ischemia, coagulative and hemorrhagic necrosis, ischemic infarction, endothelial venous damage, aneurysms and pseudo-aneurysms, and gangrene; however, it generally results in little inflammation.[90]

When inflammation is present, it manifests as a spreading, necrotizing reaction that is accompanied by mycotic aneurysms. The spores/hyphae enter the paranasal sinuses from the mucosae, where they can readily enter the orbit via the ethmoid and maxillary sinuses. In this matrix of dead organic tissue, the organism thrives and continues to spread through direct extension along wounded blood arteries. The nasolacrimal duct can also cause orbital expansion.[91] Non-septate hyphae have been identified in the cornea, iris, ciliary body, choroid,sclera, retina and optic nerve of enucleated eyes.[90]

EPIDEMIOLOGY

Mucormycosis is a fungal infection that has been documented all over the world. Mucormycosis is the third most invasive fungal infection in humans, after aspergillosis and candidiasis. Mucormycosis has been recorded from all over the world, but it is more prevalent in tropical and subtropical nations. Mucormycosis has seasonal fluctuations, according to a few studies. Between August and November, 16 out of 19 instances of rhino-orbito-cerebral mucormycosis were reported in an Israeli investigation. Mucormycosis is a fungal infection that has been documentedall over the world.[38]

Rhino-orbito-cerebral mucormycosis is the most prevalent type of mucormycosis (44–49%), followed by cutaneous (10–16%), pulmonary (10–11%), disseminated (6–11.6%), and gastrointestinal (2–11%) presentations.[39,40] Mucormycosis has been documented from every continent. A putative seasonal change in Mucorales infection has been mentioned in a few articles.[41] Mucormycosis constitutes a small proportion of invasive fungal infections in solid organ transplant recipients. The incidence of mucormycosis in patients with renal transplants ranges from 0.2to 1.2%, with liver transplants from 0 to 1.6%, with heart transplants from 0 to 0.6%, and with lung transplants from 0 to 1.5%.[85]

In Israel, Talmi et al. notedthat 16 of their 19 cases of rhino-orbito-cerebral mucormycosis occurred between August and November.[42]

In Japan, Funada and Matsudanoted a similar seasonal variation among haematology patients, with six of seven cases of Pulmonary mucormycosis having developedbetween August and September.[43]

Mucormycosis has been reported from allcorners of the world. A few papers have commented ona possible seasonal variation in Mucorales infection.[86]

DIAGNOSIS OF MUCORMICOSISCLINICAL DIAGNOSIS

A strong index of suspicion, awareness of host variables, and early assessment of clinical symptomsare all required for the diagnosis of mucormycosis. Diplopia in a diabetic patient or pleuritic discomfort in a neutropenic patient could be signs of infection, prompting the use of imaging modalities and the following collection of samples for histology, microbiology, and advanced molecular testing. As previously stated, rhinocerebral, pulmonary, soft tissue, and disseminated disease are the most common clinical presentations of Mucorales infection; however, practically any organ can be affected.[44]

Mucormycosis is characterised by tissue necrosis, however the presentation and syndrome-based approach to diagnosis lacks sensitivity and specificity. Other fungus, such as Aspergillus or Fusarium, can cause similar symptoms. Furthermore, in regions where tuberculosis is widespread, the two illnesses may coexist, as one diabetic patient recently discovered.[45]

Nonetheless, there are specific characteristics that should raise your suspicion of invasive Pulmonary mucormycosis. A history of prior voriconazole prophylaxis or the occurrence of breakthrough fungal infection in an immunocompromised patient taking anti-Aspergillus drugs areexamples.Mucorales, on the other hand, is not one of them.[46] Corzo-Leon et al. proposed a diagnostic method for diabetic patients with Rhinocerebral mucormycosis. A cranial nerve palsy, diplopia, sinus pain, proptosis, periorbital edoema, orbital apex syndrome, and ulcers of the palate are among the signs and symptoms that should be regarded "red flags."[47] Radiologically, multiple ($\geq$ 10) nodules, and pleural effusion are reportedly more common in mucormycosis. Another finding on computerized tomography (CT) scan which seems to indicate the presence of mucormycosis, is the reverse halo sign (RHS).[48] In a recent study,

where sequential thoracic CT scans were performed in leukemic patients with neutropenia, the RHS was observed in 15 of 16 patients (94%) during the first week of the disease, while other radiologic findings, such as multiple nodules, appeared later. The authors concluded that in the particular setting of neutropenic leukemic patients with pulmonary infection, the presence of the RHS on CT was a strong indicator of Pulmonary mucormycosis.[48] The CT scans of 24 patients with lung mucormycosis and 96 individuals with invasive lung aspergillosis were compared in another investigation. The RHS was more common in mucormycosis patients (54%) than in aspergillosis patients (6%, P.001), but other airway-invasive characteristics, such as clusters of centrilobular nodules, peribronchial consolidations, and bronchial wall thickening, were more common in aspergillosis patients.[49]

While these results aren't conclusive, they could be utilised as a starting point for more aggressive diagnostic laboratory procedures. The positron emission tomography-computed tomography (PET/CT) with [18F]-fluorodeoxyglucose is another new imaging method that may someday aid in the diagnosis and management of mucormycosis (FDG).[50] 8 When feasible, endobronchial ultrasound-guided fine needle aspiration is also a useful diagnostic tool.[51]

Species identification and antifungal susceptibility testing Identification of species is important for gaining a better epidemiological understanding of mucormycosis and could be useful in epidemic investigations. On culture, Mucorales fungi can easily be distinguished from Aspergillus fungi. Alvarez et al. revealed that morphological features alone can yield a high level of accuracy when by individuals with experience in fungal identification.[52] However, morphological species identification is difficult and may be associated with failures in speciation.[53] ID32Ckit (bio Merieux, Marcy l'Etoile, France) has been usedsuccessfully for the identification of Lichtheimia corymbifera and R. pusillus and API 50CH (bioMerieux).[53] forMucor species. M. circinelloides and M. rouxii failed to be distinguished by either test. ID32C combined with positive melezitose assimilation detects L. Ramosa.[54] Matrixassisted laser desorption/ionisation time-of-flight (MALDITOF) mass spectrometry is a promising tool, but is not yet validated for all Mucorales.[55] 5 Another reliable approach is the application of molecular based assays focusing on the internal transcribed spacer region.[52] M. circinelloides shows high minimum inhibitory concentrations (MIC) against posaconazole, and Rhizopus and Cunninghamella against amphotericin B.46 Some

Apophysomyces isolates have also increased MIC against amphotericin B.The role of such data is unclear for patient treatment but needs to be further analyzed.[51]

Serology

Enzyme-linked immunosorbent assays, immunoblots, and immunodiffusion tests have been evaluated with variablesuccess. Mucorales specific T cells were detected by anenzyme-linked immunospot (ELISpot) assay in three hematological patients who developed invasive mucormycosis. None of the controls had Mucorales-specific T cells. The use of such specific T cellsas surrogate diagnostic markers will be the subject of further studies.[57]

TREATMENT FOR MUCORMYCOSIS

Mucormycosis is best treated with a multimodal approach that includes reversing or stopping underlying predisposing factors (if possible), early administration of active antifungal medicines at the right dose, full excision of all infected tissues, and the use of various adjuvant therapies.[58,59,60] Patients with uncontrolled diabetes who are suspected of having mucormycosis must have their metabolic abnormalities corrected as soon as possible. In this regard, experimental research suggests that using sodium bicarbonate (together with insulin) to correct ketoacidosis, regardless of how mild or severe the acidosis is, may be linked to a better illness outcome due to Mucorales' propensity to infiltrate host tissues being reversed. 64 Corticosteroids and other immunosuppressive medicines should be discontinued as soon as feasible and to the smallest dose achievable. Early detection is critical in order to begin treatmentinterventions as soon as possible in order to prevent progressive tissue invasion and its deadly consequences.[61] 4 Corticosteroids and other immunosuppressive medications should be reduced as fast as feasible to the lowest dose possible. Early detection is critical in order to begintherapeutic measures as soon as possible in order to prevent progressive tissue invasion and its deadly consequences, minimise the impact of disfiguring corrective surgery, and improve result and survival.[62]

Chamilos et al. found that postponing effective amphotericin B-based therapy for >5 days resulted in a nearly twofold increase in 12-week mortality in patients with haematological malignancies (82.9 percent compared to 48.6 percent for those who started treatment immediately).[62] Mucoraceous fungi are resistant to most antifungals in vitro, including voriconazole. Amphotericin B is the most active drug, except for some Cunninghamella and Apophysomyces isolates. Posaconazole and isavuconazole are also active, while itraconazole and terbinafine show some activity against certain strains. There seems to be some correlation

between the degree of susceptibility of Mucorales isolates to amphotericin B and outcomes. InIn a small study by Lamothet al. MIC ≤0.5 μg/ml was significantly associated with better 6-week outcome.

A similar correlation was reported in mice, where the effi-cacy of posaconazole was higher in animals infected with strains of Rhizopus oryzae that had lower MICs.[63] There are still not enough data to make a strong recommendation, but the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) / European Confederation of Medical Mycology (ECMM) guidelines recommend susceptibility testing to guide treatment of mucormycosis and to establishepidemiological knowledge.[56]

Mucorales have many common characteristics with other moulds, including portals of entry (airways as well as disrupted mucosal and skin barriers), innate host defenses (polymorphonuclearneutrophil and mononuclear phagocytes, specific ligands in fungal spores such as pathogen- associated molecular patterns, and immune cells such as Toll-like receptors) as well as histopathological and clinical features.[64,65] R. oryzae and other Mucorales, such as Lichtheimia, Rhizomucor, and Mortierella spp., have unique virulence factors that allow them to infect patients with diabetic ketoacidosis or other forms of acidosis and exert unique host-pathogen interactions compared to other fungi, allowing for host evasion and disease progression despite treatment.[66]

In addition, mucormycosis is characterized by extensive angioinvasion that leads to vessel thrombosis and tissue necrosis.[67,68] Angioinvasion results in hematogenous dissemination of the organism, whereas necrosis of the affected tissues prevents penetration of immune cells and antifungal agents to the infection focus.[66] Certain Mucorales, such as R. oryzae, have reduced susceptibility to innate host defense as compared to other fungi, such as Aspergillus or Candida, making them more difficult to treat.[68]

The European Conference on Infections in Leukemia (ECIL-6) recommendations from 2016 as wellas the ESCMID/ECMM guidelines support using a lipidformulation of amphotericin B as first-line therapy for mucormycosis.[59,60] Liposomal amphotericin B is recommended at a dose of 5 mg/kg/day for infections of the central nervous system and as high as 10 mg/kg/day for infectionsof the peripheral nervous system. Patients in the AmbiZygo study, conducted by the French Mycosis Study Group, were given 10 mg/kg/day of liposomal amphotericin B for the first month of treatment, in addition to surgery if needed. Week 4 saw a 36 percent

response rate and week 12 saw a 45 percent response rate. Renal function impairment was detected in 40% of patients, as evidenced by a doubling of serum creatinine level (temporarily raised in 63%).[69] The study was prospective but uncontrolled, therefore the findings should be used to guide future trials. The ideal doses for antifungal medicines are still a point of contention. This is particularly true of triazoles like posaconazole and isavuconazole. Posaconazole is recommended as a salvage or maintenance therapy by ECIL-6, but the ESCMID/ECMM guidelines prescribe it as a first-line treatment (moderate recommendation) at a dose of 200 mg q6h of the oral suspension by the ESCMID/ECMM guidelines. Posaconazole's introduction of intravenous and tablet formulations has resulted in higher bioavailability and drug exposure.[70] This may strengthen the position of this triazole in the antifungal armamentarium especially against difficult-to-treat mucormycosis. Isavuconazole is a recently developed triazole, with a wide spectrum of antifungal activity including Mucorales.[71] In a multicenter, open-label trial (VITAL trial) 21 patients with mucormycosis received isavuconazole 200 mg once a day (quaque die [qd]) (after six doses of 200 mg q8h) as primary treatment and were matched with contemporaneous controls from a registry of rare fungal diseases, who had received conventional or lipid amphotericin B at a median dose 70 or 325 − 250 mg qd, respectively as primary treatment.[72] Outcomes in the two groups were similar, an isavuconazole was thus deemed to be an alternative to amphotericin B, as first-line treatment of mucormycosis. Although the results are encouraging, the study has some limitations, that is, small size and external control matching, which should be taken into account.[73]

The combination of lipid amphotericin B plus caspofungin or posaconazole, as proposed by ECIL-6, is another salvage treatment option. There is no evidence that using two antifungals as a first- line treatment is effective. A propensity score analysis was used to analyse the impact of monotherapy versus combination therapy in a group of 106 patients with hematologic malignancies, and no improved outcome was reported in the group receiving combination treatment.[74] 84 Conversely, a retrospective study of 41 cases of rhino-orbital-cerebral mucormyocsis showed a survival benefit of patients who were treated with a combination of amphotericin B with caspofungin.[75] Patients who received deferasirox, an iron-chelator, in combination with a polyene had a higher chance of survival in preclinical studies. 86 However, those who received deferasirox had a higher mortality rate in a prospective, randomised clinical trial (DEFEAT) in patients with hematologic malignancies.[76,77] Despite the study's shortcomings, both ECIL-6 and ESCMID/ECMM have

advised against using deferasirox in these individuals. Deferasirox, on the other hand, has been demonstrated to be useful as an additional therapy in diabetic patients in multiple case reports.[78]

However, a prospective, randomised clinical investigation is still needed to prove this. The use of this iron chelator in diabetic patients is only weakly supported by ESCMID/ECMM. The length of active antifungal treatment has yet to be determined. Oral formulations of active medicines, suchas posaconazole and is a vuconazole, are preferable since they can be used for several months if necessary. When surgery is required and practicable, it must be carried out with great haste. Because the Mucorales hyphae can spread infection quickly, not only necrotic tissues but also surrounding infected healthy-looking tissues should be eliminated. Surgery is very beneficial in cases with rhino-or mbitocerebral infection.[79,80]

Finally, VT-1161, a fungal CYP51 inhibitor with selective activity against R. oryzae, Lichtheimia, and Cunninghamella, shows in vitro activity against Mucorales, including R. oryzae, Lichtheimia, and Cunninghamella.[81] VT-1161 was shown to prolong survival of neutropenic mice with mucormycosis due to R.oryzae when given therapeutically[82]or prophylactically.[83]

FUTURE DIRECTIONS

The logical extension of the observations of the roles of key virulence factors, such as iron use by R. oryzae, is to develop therapeutic strategies that will translate to interventional clinical trials. Such clinical trials require considerable time and effort in study design, implementation, and analysis. The possible bene- fits of interventions that would complement existing therapies wouldbe profound for patients with mucormycosis.[84]

CONCLUSION

Infections with fungus belonging to the Mucorales and Entomophthorales orders are rare. Mucormycosis usually affects immunocompromised patients, but it can also infect healthy peoplewho have experienced trauma or have a history of environmental exposure. Because of the growing number of immunocompromised people (i.e. solid organ, bone marrow, and peripheral blood stem cell transplant recipients), more cases of mucormycosis may be seen in the future.

Early diagnosis and rigorous surgical debridement, in combination with an intravenous

amphotericin B product, remain the cornerstones of successful treatment. Hyperbaric oxygen andGM-CSF have been proposed as adjunctive treatments.

REFERENCES

1. Baker RD.Mucormycosis a new disease. JAMA, 1957; 163: 805-8.
2. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev, 2005; 18: 556-69.
3. Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, Eriksson OE, et al. A higher- level phylogenetic classificationof the fungi. Mycol Res, 2007; 111: 509-47.
4. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, 2005; 41: 634-53.
5. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev, 2005; 18: 556–69.
6. Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases.6th ed. Philadelphia, PA: Elsevier, 2005: 2979.
7. Ibrahim AS, Edwards JE, Filler SG. Zygomycosis. In: Dismukes WE, Pappas PG, Sobel JD, eds. Clinical mycology. New York, NY: Oxford University Press, 2003; 241–51
8. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology andoutcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis, 2002; 34: 909–17
9. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis, 2008; 46(June (12)): 1813-21
10. Bitar D, Van Cauteren D, Lanternier F, et al.: Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis, 2009; 15(9): 1395–401.
11. Guinea J, Escribano P, Vena A, et al.: Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS One, 2017; 12(6): e0179136.
12. Aras MH, Kara MI, Erkiliç S, Ay S. Mandibular mucormycosis in immunocompromised patients: Report of 2 cases and review of the literature. J Oral Maxillofac Surg, 2012; 70: 1362-8.

13. Viterbo S, Fasolis M, Garzino‐ Demo P, Griffa A, Boffano P, Iaquinta C, et al. Management toand outcomes of three cases of Rhinocerebral mucormycosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011; 112: e69-74.
14. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis, 2008; 47: 503-9.
15. Mayer AC. Verschimmelung (Mucedo) imlebenden Korper.Deutsches Arch Physiol, 1815; 1: 310-2.
16. Fürbinger P. Beobachtungen über Lungenmycose beim Menshen. Virchows Arch (Pathol Anat), 1876; 66: 330-65.
17. JE, Golden A, Haymaker W. Mucormycosis of the central nervous system. A report of three cases. Bull John Hopkins Hosp, 1943; 73: 405-19.
18. J. Mucormycosis: report of a case. Pediatrics, 1955; 16: 857-67.
19. Gatling RR. Gastric mucormycosis in a newborn infant; a case report. AMA Arch Pathol, 1959; 67: 249–255.
20. Maravi-Poma E, Rodriguez-Tudela JL, de Jalon JG, et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med, 2004; 30: 724–728.
21. Jatinder N.K., Srivalli N., Jyotsna G.: Rhinocerebral mucormycosis – an emerging threat. J. Oral Maxillofac. Surg. Med. Pathol, 2015, 27, 550–557.
22. González Ballester D., González-García R., Moreno García C., Ruiz-Laza L., Monje Gil F.: Mucormycosis of the head and neck: Report of five cases with different presentations. J. Craniomaxillofacial Surg, 2012; 40: 584–591.
23. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis, 2008; 47(4): 503–509.
24. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported casesClin Infect Dis, 2005; 41: 634-53.
25. Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect, 2009; 15: 41-5.
26. Sybil M, Hakim F, Koudieh M, Tleyjeh IM. Nosocomial post-traumatic Cutaneous mucormycosis : A systematic review. Scand J Infect Dis, 2008; 40: 577-82.
27. Chambers C, Reyes M, Fung M, Huntley A, Sharon V. Primary Cutaneous mucormycosis

at sites of insulin injection. J Am Dermatology, 2011; 64(5): e79-81. 28. Doi: 10.1016/j.jaad.2010.07.012.

29. de Oliveira-Neto MP, Da Silva M, Fialho Monteiro PC, Lazera M, de Almeida Paes R, Novellino AB, et al. Cutaneous mucormycosis in a young, immunocompetent girl. Med Mycol, 2006; 44: 567-70.
30. Cox GM, Kauffman CA, Thorner AR. Mucormycosis. UpToDate. https: //www-uptodate-com.ezproxy.galter.northwestern.edu/contents/mucormycosis-zygomycosis. Published 2018. Accessed October 20, 2018.
31. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect, 2014; 20(Supl 3): 5–26.
32. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg, 1994; 57(4): 1044–1050.
33. Mills SEA, Yeldandi AV, Odell DD. Surgical Treatment of Multifocal Pulmonary Mucormycosis. Ann Thorac Surg, 2018; 106(2): e93–e95.
34. Lee DG, Choi JH, Choi SM, Yoo JH, Kim YJ, Min CK, et al. Two cases of Disseminated mucormycosis in patients following allogeneic bone marrow transplantation. J Korean Med Sci, 2002; 17: 403‑6.
35. Gupta KL, Joshi K, Pereira BJ, Singh K. Disseminated mucormycosis presenting with acuterenal failure. Postgrad Med J, 1987; 63: 297‑9.
36. Pak J, Tucci VT, Vincent AL, Sandin RL, Greene JN. Mucormycosis in immunochallenged patients. J Emerg Trauma Shock, 2008; 1: 106‑13.
37. Nichols L, Ocque RZ, Daly I. Zygomycosis associated with HIV infection and liver transplantation. Patholog Res Int, 2011; 2011: 545981.
38. ChanderJ, KaurJ, AttriA, Mohan H. Primary cutaneous zygomycosis from a tertiary care centre in north‑west India. Indian J Med Res, 2010; 131: 765‑70.
39. 4. Talmi YP, Goldschmied-Reouven A, Bakon M, Barshack I, Wolf M, Horowitz Z, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg, 2002; 127: 22-31.
40. SugarAM. Agents of mucormycosis and related species. In: Mandell GI, BennettJE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease.5th ed. New York: Churchill Livingstone, 2000; 2685-95.

41. Funada H, Matsuda T. Pulmonary mucormycosis in ahematology ward. Intern Med, 1996; 35: 540–4.
42. Talmi YP, Goldschmeid-Reouven A, Bakon M et al. Rhino-orbital and rhino-orbito-cerebralmucormycosis. Otolaryngol Head Neck Surg, 2002; 127: 22–31.
43. Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Med, 1996; 35: 540–4.
44. Petrikkos G, Skiada A, Lortholary O et al. Epidemiology and clinicalmanifestations of mucormycosis. Clin Infect Dis, 2012; 54: S23–S34.
45. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcomeof zygomycosis: areview of 929 reported cases. Clin Infect Dis, 2005; 41: 634–653.
46. Chamilos G, Marom EM, Lewis RE et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer.Clin Infect Dis, 2005; 41: 60–66.
47. Corzo-Leon DE, Chora-Hernandez LD, Rodriguez-Zulueta P, Walsh TJ.Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomesof reported cases. Med Mycol, 2017; doi: 10.1093/mmy/myx017.
48. Legouge C, Caillot D, Chretien ML et al. The reversed halo sign: pathognomonic pattern of Pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis, 2014; 58: 672–678.
49. 7. Jung J, Kim Y, Lee HJ et al. Comparison of computed tomographic findings in Pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect, 2015; 21: e11–684.e18.
50. Liu Y, Wu H, Huang F, Fan Z, B. Utility of 18F- FDG PET/CT in diagnosis and management of mucormycosis. Clin Nucl Med, 2013; 38: e370–e371.
51. Alvarez E, Sutton DA, Cano J et al. Spectrum of zygomycete species identified in clinically significant specimens in the United States.J Clin Microbiol, 2009; 47: 1650–1656.
52. Yang M, Lee JH, Kim YK, CS, Huh HJ, Lee NY. Identification of mucorales from clinical specimens: a 4-year experience in a single institution. Ann Lab Med, 2016; 36: 60–63.
53. Ramani R, Gromadzki S, Pincus DH, Salkin IF, Chaturvedi V. Efficacyof API 20C and ID 32C systems for identification of common and rareclinical yeast isolates. J Clin Microbiol, 1998; 36: 3396–3398.
54. 4. Schwarz P, Lortholary O, Dromer F, Dannaoui E. Carbon assimilationprofiles as a tool for identification of zygomycetes. J Clin Microbiol, 2007; 45: 1433–1439.

55. Schr¨odl W, Heydel T, Schwartze VU et al. Direct analysis and identification of
56. pathogenic Lichtheimia species by matrix-assisted laser desorption ionization "Time of Flight" analyzer-mediated mass spectrometry. J Clin Microbiol, 2012; 50: 419–427.
57. Vitale RG, de Hoog GS, Schwarz P et al. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol, 2012; 50: 66–75.
58. Potenza L, Vallerini D, Barozzi P et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogatediagnostic marker in high-risk patients. Blood, 2011; 118: 5416–5419.
59. Tissot F, Agrawal S, Pagano L et al. ECIL-6 guidelines for the treatment of invasive candidiasis, and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017; 102: 433–444.
60. Cornely OA, Arikan-Akdagli S, Dannaoui E et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis. Clin Microbiol Infect, 2014; 20: 5– 26.
61. . Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficultto cure than morecommon mycoses? Clin Microbiol Infect, 2014; 20: 74–81.
62. Gebremariam T, Lin L, Liu M et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest, 2016; 126: 2280–2294.
63. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis, 2008; 47: 503–509.
64. Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. ClinMicrobiol Infect, 2006; 12: 404–409.
65. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against zygomycetes. Clin Infect Dis, 2012; 54: S61–S66.
66. Gebremariam T, Liu M, Luo G et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest, 2014; 124: 237–250.
67. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of Pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect, 2009; 59: 134–138.
68. Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to

oxidative damage.AntimicrobAgents Chemother, 2008; 52: 722–724.

69. Lanternier F, Poiree S, Elie C et al. Prospective pilot study of high-dose(10 mg/kg/day) liposomal amphotericin B (L-Amb) for the initial treatment of mucormycosis. J Antimicrob Chemother, 2015; 70: 3116–3123.
70. Wiederhold NP. Pharmacokinetics and safety of posaconazole delayedrelease tablets for invasive fungal infections. Clin Pharmacol, 2016; 8: 1–8.
71. Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacother, 2015; 35: 1037–1051.
72. Marty FM, Ostrosky-Zeichner L, Cornely OA et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis, 2016; 16: 828–837.
73. Roilides E, Antachopoulos C. Isavuconazole: an azole active against mucormycosis. LancetInfect Dis, 2016; 16: 761–762.
74. . Kyvernitakis A, Torres HA, Chamilos G et al. Initial use of combinationtreatment does not impact survival of 106 patients with hematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect, 2016; 22: e1–811.e
75. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis, 2008; 47: 364–371.
76. Ibrahim AS, Gebremariam T, Fu Y et al. The iron chelator deferasiroxprotects mice from mucormycosis through iron starvation. J Clin Invest, 2007; 117: 2649–2657.
77. Spellberg B, Ibrahim AS, Chin-Hong PV et al. The Deferasirox- AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized,double-blinded, placebo-controlledtrial. J Antimicrob Chemother, 2012; 67: 715–722.
78. Spellberg B, Andes D, Perez M et al. Safety and outcomes of open-labeldeferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother, 2009; 53: 3122–3125.
79. Gil-Lamaignere C, Simitsopoulou M, Roilides E et al. Interferon- gamma and granulocyte- macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis, 2005; 191: 1180–1187.
80. Roilides E, Antachopoulos C, Simitsopoulou M. Pathogenesis and hostdefence against Mucorales: the role of cytokines and interaction withantifungal drugs. Mycoses, 2014; 57: 40–47.

81. Fothergill AW, McCarthy DI, Sutton DA et al. The fungal Cyp51 inhibitor VT-1161 demonstrates in vitro synergy with tacrolimus against Aspergillus spp. and members of the order Mucorales, Abstract in 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (American Society for Microbiology) Washington, DC.
82. Gebremariam T, Wiederhold NP, Fothergill AW et al. VT-1161 protectsimmunosuppressed mice from Rhizopus arrhizus var. arrhizus infection. Antimicrob Agents Chemother, 2015; 59: 7815–7817.
83. Gebremariam T, Alkhazraji S, Lin Lin et al. Prophylactic treatmentwith VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection. Antimicrob Agents Chemother, 2017doi: 10.1128/AAC.00390-17.
84. Ashraf S. Ibrahim,Brad Spellberg,Clinical Infectious Diseases, 2012; 54(S1): S16–22.
85. Wajszczuk CP, Dummer JS, Ho M, Van Thiel TE, Iwatsuki S, Shaw B. Fungal infections in liver transplant recipients. Transplantation, 1985; 40: 347–53.
86. Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Med, 1996; 35: 540–4.
87. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectiveson mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev, 2005; 18: 556-6.
88. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, 2005; 41: 634-53.
89. Sugar AM. Agents of mucormycosis and related species.In: Mandell GL, Bennet JE, Dolin R, editors. Principals and practice of infectious diseases. 4th ed. New York: ChurchilLivingstone, 1995; 2311-21.
90. Schwartz JN, Donnelly EH,Klintworth GK. Ocularand orbital phycomycosis. Surv Ophthalmol, 1977; 22: 3-28.
91. Bergstrom LV, Hemenway WG, Barnhart RA. Rhinocerebral and otologic mucormycosis. Ann otol Rhinol Latyngol, 1970; 79: 70-81.
92. Kontoyiannis DP, Lewis RE. Agents of Mucormycosis and Entomophthoramycosis. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, Pa: Elsevier/Saunders, 2015; 2909–291.